Home  Clinical trials Casodex™ (bicalutamide)
|
|
| Casodex™ (bicalutamide) Clinical Trial report summaries |
Casodex™ (bicalutamide) is an oral non-steroidal anti-androgen for prostate cancer. Casodex™ was first launched in 1995 as a combination treatment (with surgical or medical castration) for advanced prostate cancer and subsequently launched as monotherapy for the treatment of earlier stages of the disease.
Please consult the prescribing information for the country concerned for guidance on the approved use of Casodex™ (bicalutamide). | Study Number | Completed Clinical Trial Report Summaries | 176334/0306 | A Multicentre, Randomised Trial to Compare the Effect of Two Blinded Doses of CASODEX (AstraZeneca 176,334; 100 mg and 150 mg po daily) and Castration in the Treatment of Advanced Carcinoma of the Prostate | 176334/0307 | A multicentre randomised trial to compare the effect of two blinded doses of CASODEX (AstraZeneca 176,334; 100 mg and 150 mg orally daily) and castration in the treatment of advanced carcinoma of the prostate | 7054IL/0009 | A multicentre, randomised, comparative trial to assess the tolerance (maximum well-tolerated dose), efficacy and pharmacokinetics of escalating doses of CASODEX (300 mg po daily, increasing by 150 mg intervals) versus castration (medical or surgical) in the treatment of advanced carcinoma of the prostate | 7054IL/0023 | A Randomised, Double-blind Comparative Trial of Bicalutamide (CASODEX]) versus Placebo in Patients with Early Prostate Cancer (7054IL/0023). | 7054IL/0024
| A Randomised, Double-blind, Parallel-group Trial comparing CASODEX] 150 mg Once Daily with Placebo in Patients with Non-metastatic Prostate Cancer (7054IL/0024). | 7054IL/0025
| A Randomised, Double-blind, Parallel-group Trial comparing CASODEX] 150 mg Once Daily with Placebo in Patients with Non-metastatic Prostate Cancer (SPCG-6) (7054IL/0025). | 7054IL/0038 | A randomised, double-blind, parallel-group trial to investigate the efficacy and tolerability of radiotherapy as prophylactic treatment against the development of CASODEX monotherapy induced gynaecomastia and breast pain in prostate cancer patients. | 7054IL/0044 | A randomised, double-blind, placebo controlled, parallel-group, multicentre Phase II study to assess the dose response relationship of tamoxifen (oral tablet) in the prophylactic treatment of gynaecomastia and breast pain associated with CASODEX 150 mg (oral tablet), and to assess the tumour control efficacy of the combination in patients with prostate cancer | 7054IT/0002 | A randomised, double blind, parallel group, multicentre trial comparing the efficacy and tolerability either of NOLVADEX® or of ARIMIDEX® or of Placebo in preventing the development (worsening) of gynecomastia in patients being treated with CASODEX® 150 mg monotherapy for prostate cancer | 7054US/0004 | A Multicenter, Randomized, Open-label Trial to Compare Bone Mineral Density and Fat Free Mass in Men GivenReceiving Either Goserelin Acetate (ZOLADEXTM) 10.8- mg Depot or Bicalutamide (CASODEXTM) 150 mg for Treatment of Prostate Cancer. | 7054TR/01 | An Open Randomised Trial to Compare the Value of Prophylactic versus Therapeutic Breast Radiotherapy in CASODEX™ Monotherapy Induced Gynecomastia and/or Breast Pain in Prostate Cancer Patients. (COMART) . | C-15-32 | A randomised, double-blind, comparative, multicentre study of Casodex + LH-RH agonist combination therapy vs LH-RH agonist monotherapy in subjects who had not been treated for advanced prostate cancer |
|
|
|
|